Dr. Butt obtained a Ph.D. degree in Molecular Biology from The University of Glasgow, Scotland, UK. He was a Staff Fellow at the National Institutes of Health, Bethesda, MD, before joining SmithKline Beckman (now GSK) Pharmaceuticals, where he was an Assistant Director in Research and Development. Dr. Butt also served as an Adjunct Professor Biochemistry and Biophysics, University of Pennsylvania Medical School, Philadelphia (1989-2000). He has published approximately 100 papers in life sciences research, and holds several patents. Dr. Butt serves as an Adjunct Professor in Biomedical Engineering at Drexel University, Philadelphia and is active in a number of national and regional professional organizations, including several dedicated to biotechnology. At Progenra he is spearheading the effort to target ubiquitin pathway enzyme for immune oncology. Progenra’s USP7 small molecules inhibitors have demonstrated dual anti-tumor activities. USP7 inhibitors directly block tumor cell growth as well as suppress Tregs thereby unleashing anti-tumor Teffector responses. Data shows that USP7 inhibitors have potent anti-tumor activity as a small molecule, single agent.